Pharmacokinetic and safety assessment of substances prohibited by the World Anti-Doping Agency in healthy volunteers: A proof-of-concept study

The primary objective of this study is to evaluate the **exposure** to substances prohibited by the World Anti-Doping Agency in **healthy volunteers**. This investigation is clinically relevant as it aims to understand the potential effects and risks associated with these substances, which are critical for ensuring the safety and integrity of sports and athletic performance. The study does not specify any secondary objectives.

The clinical trial involves **healthy volunteers** as the study population, specifically focusing on male participants. The age range of the participants is categorized as adults, although the exact age range is not specified. The sponsor has not provided information regarding the total number of participants involved in the trial. Participants were selected based on their general health status, ensuring they are not part of a vulnerable population. There are no specific lifestyle considerations such as diet, physical activity, or habits mentioned for this trial. The sponsor has not disclosed any key inclusion or exclusion criteria for the study.

The clinical trial is designed to evaluate the exposure to substances prohibited by the World Anti-Doping Agency in **healthy volunteers**. This study is a Phase 3 trial, which is expected to commence recruitment on July 1, 2025, and conclude by June 30, 2027. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. Participants will be randomly assigned to either the treatment group or the control group, with neither the participants nor the researchers aware of the group assignments, thereby minimizing bias.

The sequence of study visits begins with an inclusion visit, also known as the screening visit, where potential participants are assessed for eligibility based on predefined criteria. This visit is crucial for ensuring that only suitable candidates are enrolled in the study. Following successful screening, participants will undergo a series of follow-up visits at regular intervals. These visits are designed to monitor the participants' health, assess the effects of the intervention, and ensure adherence to the study protocol. The end-of-study visit marks the conclusion of the participant's involvement, where final assessments are conducted to gather comprehensive data on the study's outcomes.

The expected length of participant involvement in the trial is approximately two years, aligning with the overall trial duration. However, certain conditions may lead to early termination from the study, such as adverse events, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical guidelines and regulatory requirements, ensuring the safety and well-being of all participants throughout the study period.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements cannot be provided.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included in the data. As such, these aspects cannot be detailed in the context of this clinical trial.

The clinical trial is designed to assess efficacy within a Phase 3 framework. The trial is scheduled to commence recruitment on July 1, 2025, with an estimated completion date of June 30, 2027. Efficacy will be evaluated through specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The methods and tools for measuring efficacy, such as validated scales or laboratory tests, are not specified in the available information. The trial's focus on efficacy assessment aligns with the rigorous standards expected in a Phase 3 clinical trial, ensuring that the outcomes are scientifically robust and clinically relevant.